Chris Raymond
Stock Analyst at Raymond James
(2.99)
# 1,367
Out of 5,116 analysts
9
Total ratings
66.67%
Success rate
66.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Downgrades: Outperform | $142 → $123 | $60.38 | +103.71% | 3 | Nov 14, 2025 | |
| SION Sionna Therapeutics | Initiates: Strong Buy | $45 | $42.26 | +6.48% | 1 | Sep 3, 2025 | |
| TYRA Tyra Biosciences | Initiates: Strong Buy | $35 | $30.82 | +13.56% | 1 | Sep 3, 2025 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $102.97 | +1.97% | 1 | Sep 3, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Strong Buy | $23 | $8.88 | +159.01% | 1 | Sep 3, 2025 | |
| COGT Cogent Biosciences | Initiates: Strong Buy | $30 | $35.91 | -16.46% | 1 | Sep 3, 2025 | |
| BHVN Biohaven | Initiates: Strong Buy | $75 | $11.83 | +533.98% | 1 | Sep 3, 2025 |
Monopar Therapeutics
Nov 14, 2025
Downgrades: Outperform
Price Target: $142 → $123
Current: $60.38
Upside: +103.71%
Sionna Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $45
Current: $42.26
Upside: +6.48%
Tyra Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $35
Current: $30.82
Upside: +13.56%
Nuvalent
Sep 3, 2025
Initiates: Outperform
Price Target: $105
Current: $102.97
Upside: +1.97%
Kalaris Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $23
Current: $8.88
Upside: +159.01%
Cogent Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $30
Current: $35.91
Upside: -16.46%
Biohaven
Sep 3, 2025
Initiates: Strong Buy
Price Target: $75
Current: $11.83
Upside: +533.98%